MGMT and glioblastoma: VAL-083 is known to penetrate the blood–brain barrier and to accumulate in the cerebrospinal fluid and brain parenchyma [39]; it is currently tested in clinical trials for recurrent GBM (NCT02717962) as well as for treatment-naïve MGMT promoter unmethylated GBM patients (NCT03050736).